Laura A. Jenny

Laura A. Jenny

Auto-generated profile, based on publicly available information

Laura A. Jenny

Columbia University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2023 in EMBO Molecular Medicine
Verified
Journal Article
Open access
YKYang Kong
Yang Kong
PLPei-Kang Liu
Pei-Kang Liu
YLYao Li
Yao Li
NNNicholas D Nolan
Nicholas D Nolan
Peter M.J. QuinnPeter M.J. Quinn
Peter M.J. Quinn
STStephen Tsang
Stephen Tsang
Iron accumulation causes cell death and disrupts tissue functions, which necessitates chelation therapy to reduce iron overload. However, clinical utilization of deferoxamine (DFO), an iron chelator, has been documented to give rise to systemic adverse effects, including ocular toxicity. This study provided the pathogenic and molecular basis for DFO‐related retinopathy and identified retinal pigment epithelium (RPE) as the target tissue in DFO‐related retinopathy. Our modeling demonstrated the susceptibility of RPE to DFO compared with the neuroretina. Intriguingly, we established upregulation of hypoxia inducible factor (HIF) 2α and mitochondrial deficit as the most prominent pathogenesis underlying the RPE atrophy. Moreover, suppressing hyperactivity of HIF2α and preserving mitochondrial dysfunction by α‐ketoglutarate (AKG) protects the RPE against lesions both in vitro and in vivo . This supported our observation that AKG supplementation alleviates visual impairment in a patient undergoing DFO‐chelation therapy. Overall, our study established a significant role of iron deficiency in initiating DFO‐related RPE atrophy. Inhibiting HIF2α and rescuing mitochondrial function by AKG protect RPE cells and can potentially ameliorate patients' visual function.

25 May 2023 in Vision Research
Verified
Journal Article
Closed access
ASAlizeh Shamshad
Alizeh Shamshad
CKChaerim Kang
Chaerim Kang
LJLaura A. Jenny
Laura A. Jenny
EPElijah M. Persad-Paisley
Elijah M. Persad-Paisley
STStephen Tsang
Stephen Tsang

23 February 2022 in Human Molecular Genetics
Verified
Journal Article
Closed access
PDF file
XCXuan Cui
Xuan Cui
HKHye Jin Kim
Hye Jin Kim
CCChia-Hua Cheng
Chia-Hua Cheng
LJLaura A Jenny
Laura A Jenny
JCJose Ronaldo Lima de Carvalho
Jose Ronaldo Lima de Carvalho
STStephen Tsang
Stephen Tsang
Retinitis pigmentosa (RP) is caused by one of many possible gene mutations. The National Institutes of Health recommends high daily doses of vitamin A palmitate for RP patients. There is a critical knowledge gap surrounding the therapeutic applicability of vitamin A to patients with the different subtypes of the disease. Here, we present a case report of a patient with RP caused by a p.D190N mutation in Rhodopsin (RHO) associated with abnormally high quantitative autofluorescence values after long-term vitamin A supplementation. We investigated the effects of vitamin A treatment strategy on RP caused by the p.D190N mutation in RHO by exposing Rhodopsin p.D190N (RhoD190N/+) and wild-type (WT) mice to experimental vitamin A-supplemented and standard control diets. The patient’s case suggests that the vitamin A treatment strategy should be further studied to determine its effect on RP caused by p.D190N mutation in RHO and other mutations. Our mouse experiments revealed that RhoD190N/+ mice on the vitamin A diet exhibited higher levels of autofluorescence and lipofuscin metabolites compared to WT mice on the same diet and isogenic controls on the standard control diet. Vitamin A supplementation diminished photoreceptor function in RhoD190N/+ mice while preserving cone response in WT mice. Our findings highlight the importance of more investigations into the efficacy of clinical treatments like vitamin A for patients with certain genetic subtypes of disease and of genotyping in the precision care of inherited retinal degenerations.

20 July 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
WNWei Kiong Ngo
Wei Kiong Ngo
LJLaura A. Jenny
Laura A. Jenny
AKAngela H Kim
Angela H Kim
MKMasha Kolesnikova
Masha Kolesnikova
VGVivienne C. Greenstein
Vivienne C. Greenstein
STStephen Tsang
Stephen Tsang

18 July 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
YLYao Li
Yao Li
RYRichard R. Yang
Richard R. Yang
YLYong-Shi Li
Yong-Shi Li
CHChun-Wei Hsu
Chun-Wei Hsu
LJLaura A. Jenny
Laura A. Jenny
STStephen Tsang
Stephen Tsang
Patient-specific induced pluripotent stem cell–derived (iPSC-derived) cell lines allow for therapies to be tailored to individual patients, increasing therapeutic precision and efficiency. Bietti crystalline dystrophy (BCD) is a rare blinding disease estimated to affect about 67,000 individuals worldwide. Here, we used iPSC-derived retinal pigment epithelium (iRPE) cells from patients with BCD to evaluate adeno-associated virus–mediated (AAV-mediated) gene augmentation therapy strategies. We found that BCD iRPE cells were vulnerable to blue light–induced oxidative stress and that cellular phenotype can be quantified using 3 robust biomarkers: reactive oxygen species (ROS), 4-hydroxy 2-nonenal (4-HNE) levels, and cell death rate. Additionally, we demonstrated that AAV-mediated gene therapy can significantly reduce light-induced cell death in BCD iRPE cells. This is the first proof-of-concept study to our knowledge to show that AAV- CYP4V2 gene therapy can be used to treat light-induced RPE damage in BCD. Furthermore, we observed significant variability in cellular phenotypes among iRPE from patients with BCD of divergent mutations, which outlined genotype-phenotype correlations in BCD patient–specific cell disease models. Our results reveal that patient-specific iRPE cells retained personalized responses to AAV-mediated gene therapy. Therefore, this approach can advance BCD therapy and set a precedent for precision medicine in other diseases, emphasizing the necessity for personalization in healthcare to accommodate individual diversity.

5 February 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
SSShao-Yu Sung
Shao-Yu Sung
LJLaura A. Jenny
Laura A. Jenny
YCYo-Chen Chang
Yo-Chen Chang
Nan-Kai WangNan-Kai Wang
Nan-Kai Wang
PLPei-Kang Liu
Pei-Kang Liu
A 25-year-old female with diabetes and hypertension presented with progressive painless blurred vision in her left eye ten days after she received her third dose of the SARS-CoV-2 mRNA vaccine BNT162b2 (Pfizer-BioNTech). The clinical examination confirmed the diagnosis of Central Retinal Vein Occlusion (CRVO) complicated with macular edema. Three doses of anti-vascular endothelial growth factor (VEGF) were injected intravitreally. Visual acuity was improved from 20/100 to 20/30, but recurrence was noted at 6 months. Several cases of retinal vein occlusion (RVO) after COVID-19 vaccination have been reported. However, the present case is the youngest female individual documented to have CRVO after SARS-CoV-2 vaccination. This case demonstrates that the macular edema might be recurrent in patients with risk factors for CRVO who receive SARS-CoV-2 vaccination, suggesting the need for careful consideration of the treatment strategy and close follow-up. Although the definite pathogenesis still needs to be carefully determined, this report highlights the possible association between RVO and mRNA-based COVID-19 vaccination, even in young individuals.